Symbols

WW

WW·NASDAQ

--(--)

WW fundamentals

WW Q4 2025 Earnings

WW (WW) released its earnings on Mar 16, 2026: revenue was 162.81M (YoY --), beat estimates; EPS was -0.58 (YoY --), beat estimates.

Revenue / YoY

162.81M

EPS / YoY

-0.58

Report date

Mar 16, 2026

WW Earnings Call Summary for Q4,2025

Clinical Growth Dominates: Q1 2026 clinical subscribers reached 200,000 (~100% YoY growth), with 50% of new Med+ members being brand-new.
Superior Outcomes: Members using GLP-1 Success program lost 29% more weight than those on medication alone.
Financial Resilience: Adjusted EBITDA of $18M in Q4, with 2026 guidance for $105-115M.
Strategic Shifts: Front-loaded Q1 marketing spend ($40-45M of annual budget) to reposition brand, with ARPU growth driven by clinical (4x behavioral).
B2B Expansion: Pipeline momentum with UnitedHealth and employer subsidies, despite behavioral subscriber decline (-26% YoY).

Earnings

EPS

Revenue

Revenue & Expenses

WW has released its 2025 Q4 earnings report, with revenue of 162.81M, reflecting a YoY change of -11.71%, and net profit of -5.83M, showing a YoY change of -123.22%. The Sankey diagram below clearly presents WW's revenue sources and cost distribution.

Key Indicators

WW (WW) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

WW (WW)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

WW (WW)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

WW (WW)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown